Formycon

Let's see what happens...

Changes at Deutsche Börse:

The used car dealer Auto1 $AG1 (+3,11 %) and the biotech company Evotec $EVT (+1,24 %) return to the small cap index on 23.12.24 MDax of the German Stock Exchange. They will replace the metal recycler Befesa $BFSA (+2,16 %) and the automotive and industrial supplier Stabilus $STM (+0,95 %) which will be relegated to the small-cap index SDax, as announced by Deutsche Börse subsidiary ISS Stoxx on Wednesday evening.

Evotec was only forced to leave the MDax in September, but since then the shares have risen again in view of a possible sale of the company. Auto1, on the other hand, was previously listed on the MDax until spring 2022.

In addition, the SDAX also has three newcomers. The software company Nexus $NXU (+1,53 %) the scientific publisher Springer Nature
$SPG (+1,06 %) and the biosimilars specialist Formycon $FYB (+0,49 %) .

On the other hand, the telecom equipment supplier Adtran Holdings
$ADTN (-3,05 %) the office furniture mail order company Takkt
$TTK (-2,29 %) and the hydrogen specialist Thyssenkrupp Nucera
$NCH2 (-3,89 %) .

In the DAX there are no changes.

The changes will take effect on December 23 of this year.

Handelsblatt

Another depot update. Values are not quite correct but the reference value is. The crypto values are completely wrong but I have no idea where the entry price is (made kind of annoying at Coinbase). The best positions at the moment are $SOFI (+1,24 %)
$FTNT (+1,49 %)
$D05 (+0,1 %) . The interesting values for me are $BNTX (+0,93 %)
$FYB (+0,49 %)
$SNOW (+0,59 %)

$FYB (+0,49 %) Formycon has much more to offer, both Novartis/Sandoz and Fresenius are interested in the company according to stock market information. However, a takeover now would be much too early and bad for shareholders. Now already a biosimilar in the market, more will follow from 2024/2025 it will be really interesting. The 16% increase in the share price today was just the beginning. Price targets 500 - 1000 €. Thus a 10 bagger. Read the 60 page report "Formycon the next Tenbagger", available at Amazon.

Besides BioNTech, the Formycon AG share is my second Corona bet. Unfortunately, it has not yet worked out in this case. With an entry at approx. 65€, I am now at approx. -20% return 🆘.

What does Formycon do?

"Formycon continues to advance the development of its COVID-19 drug candidate FYB207. An expansion of preclinical efficacy testing is planned, the company reported Wednesday. Most recently, FY207 had produced multiple positive results, but at the same time is still far from being used in everyday life."

That sounds bullish for now. The results of the first clinical studies and a possible subsequent approval will determine to what extent a price rocket will ignite here.

https://www.4investors.de/nachrichten/boerse.php?sektion=stock&ID=155248